Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.97 |
| ▸ | TK2 | O00142 | 2/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.64 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.64 |
| ▸ | TK1 | P04183 | 2/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18032577 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL2056544 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL2579194 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL12315567 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL3389861 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL97335 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL2056540 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL654674 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL97336 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL5165189 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382286-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140336143-A1 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | GILEAD PHARMASSET LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | PHARMASSET, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7638502-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7211570-B2 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | PHARMASSET, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | PYGM 1497/4885TK2 90/4885P2RY6 1195/4885 |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | UMPS, ENTPD5, TK1 | PYGM 2479/4885TK2 54/4885P2RY6 1864/4885 |
| US-20140336143-A1 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | UMPS, ENTPD5, TK1 | PYGM 2479/4885TK2 54/4885P2RY6 1864/4885 |
| US-20100168052-A1 | Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation | UMPS, ENTPD5, TK1 | PYGM 2479/4885TK2 54/4885P2RY6 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.